Efficacy of bosentan in the prevention of new digital ulcers in a patient with systemic sclerosis (case report)


Authors: S. Skácelová 1;  R. Bečvář 1;  J. Štork 2
Authors‘ workplace: Revmatologický ústav Praha 1;  Dermatovenerologická klinika 1. LF UK, Praha 2
Published in: Čes. Revmatol., 20, 2012, No. 2, p. 74-81.
Category: Case Report

Overview

Digital ulcers (DU) and Raynaud’s phenomenon are clinical manifestations of digital vasculopathy in patients with systemic sclerosis. They occur in about one third of patients. This is a very painful condition associated with serious complications such as infection or gangrene. Digital ulcers significantly limit the functional ability of the hand and reduce the patients’ quality of life. Approximately 1-2% of patients with DU require amputation of the distal phalanx. Systemic pharmacotherapy of trophic digital ulcers is based on the use of calcium channel blockers, intravenous prostanoids, analgesics, antiplatelet agents, and antibiotics. Bosentan, a dual endothelin receptor antagonist, is the new hope for patients with DU. Bosentan significantly reduces the formation of new ulcers. It is suitable for patients who suffer from multiple recurrent digital ulcers. In this article the authors present an overview of literature data on the epidemiology, pathophysiology and treatment of digital vasculopathy in systemic sclerosis. The issue of treatment of recurrent digital ulcers in systemic sclerosis is documented by a case report.

Key words:
systemic sclerosis, digital ulcers, bosentan


Sources

1. Steen V, Denton CP, Pope JE and Matucci-Cerinic M. Digital ulcers: overt vascular disease in systemic sclerosis. Rheumatology 2009; 48 (Suppl 3):iii19-iii24.

2. Nihtyanova SI, Brough GM, Black CM, Denton CP. Clinical burden of digital vasculopathy in limited and diffuse cutaneuous systemic sclerosis. Ann Rheum Dis 2008;67:120-3.

3. Sunderkötter C, Hergott I, Brückner C, et al. Comparison of patients with and without digital ulcers in systemic sclerosis: detection of possible risk factors. Br J Dermatol 2009; 160(4):835-843.

4. Pope J, Khimdas S, Gardiny S, Bonner A, Baron M. Associations with digital ulcers (DU) in a large kohort of systemic sclerosis (SSc): results from the canadian scleroderma research group (CSRG). Proceedings of the 1st Systemic Sclerosis World Congress, Florence, Italy 2010.

5. Amanzi L, Braschi F, Fiori G, et al. Digital ulcers in scleroderma: staging, characteristics and sub-setting through observation of 1614 lesions. Rheumatology 2010; 49(7):1374-1382.

6. Walker UA, Tyndall A, Czirják L, et al. Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group database. Ann Rheum Dis 2007;66(6):754-763.

7. Galluccio F, Matucci-Cerinic M. Registry evaluation of digital ulcers in systemic sclerosis. J Rheumatol 2010; 2010.pii:363679. Epub 2010 Aug 25

8. Hachulla E, Clerson P, Launay D, et al. Natural history of ischemic digital ulcers in systemic sclerosis: single-center retrospective longitudinal study. J Rheumatol 2007; 34:2423-30.

9. Schiopu E, Impens AJ, Philips K. Digital ischemia in scleroderma spectrum of diseases. Int J Rheumatol. 2010;2010. pii: 923743. Epub 2010 Aug 31.

10. Lau CS, McLaren M, Saniabadi A and Belch JJF. Increased whole blood platelet aggregation in patients with Raynaudęs phenomenon with or without systemic sclerosis. Scandinavian Journal of Rheumatology 1993;22(3):97-101.

11. Rodnan GP, Myerowitz RL, Justh GO. Morphologic changes in the digital arteries of patients with progressive systemic sclerosis (scleroderma) and Raynaudęs phenomenon. Medicine 1980; 56(6):393-408.

12. Matucci-Cerinic M and Seibold JR. Digital ulcers and outcomes assessment in scleroderma. Rheumatology 2008; 47:v46-v47.

13. Herrick LA, Roberts Ch, Tracey A, et al. Lack of agreement between rheumatologists in defining digital ulceration in systemic sclerosis. Arthritis Rheum 2009;60(3):878-882.

14. Korn JH, Mayes M, Matucci-Cerinic M et al for the RAPIDS-1 Study Group. Digital ulcers in systemic sclerosis. Prevention by treatment with bosentan, an oral endothelin receptor antagonist. Arthritis Rheum 2004;50 (12):3985-3993.

15. Bielecka-Kowal O, Landewé R, Avouac J, et al. EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR). Ann Rheum Dis 2009;68(5):620-628.

16. Thompson AE, Shea B, Welch V, et al. Calcium-channel blockers for Raynaudęs phenomenon in systemic sclerosis. Arthritis Rheum 2001;44:1841-1847.

17. Dziadzio M, Denton CP, Smith R, et al. Losartan therapy for Raynaudęs phenomenon and scleroderma: clinical and biochemical finding in a fifteen-week, randomized, parallel-group, controlled trial. Arthritis Rheum 1999;42:2646-55.

18. Gliddon AE, Doré CJ, Black CM, et al. Prevention of vascular damage in scleroderma and autoimmune Raynaudęs phenomenon: a multicenter, randomized, double-blind, placebo-controlled trial of the angiotensin-converting enzyme inhibitor quinapril Arthritis Rheum 2007;56(11): 3837-3846.

19. Impens AJ, Phillips K, Schiopu E. PDE-5 inhibitors in scleroderma Raynaudęs phenomenon and digital ulcers: current status of clinical trials. Int J Rheum 2011;2011: 392542. Epub 2011 Nov 2.

20. Bueckner CS, Becker MO, Kroencke T, et al. Effect of sildenafil on digital ulcers in systemic sclerosis: analysis from a single centre pilot study. Ann Rheum Dis 2010;69(8):1475-1478.

21. Herrik AL. Contemporary management of Raynaudęs phenomenon and digital ischaemic complications. Curr Opin Rheumatol 23:555-561.

22. Arefiev K, Fiorentino DF and Chung L. Endothelin receptor antagonists for the treatment of Raynaudęs phenomenon and digital ulcers in systemic sclerosis. Int J Rheumatol 2011;2011:201787. Epub 2011 Oct 27.

23. Yamane K, Miyauchi T, Suzuki N, et al. Significance of plasma endothelin-1 levels in patients with systemic sclerosis. J Rheumatol 1992;19:1566-71.

24. Abraham DJ, Krieg T, Distler J and Distler O. Overview of pathogenesis of systemic sclerosis. Rheumatology 2009 Jun 48(suppl3) iii3-7.

25. Biondi ML, Marasini B, Bassani C and Agostoni A. Increased plasma endothelin levels in patients with Raynaudęs phenomenon. N Engl J Med 1991;324(16):1139-1140.

26. Matucci-Cerinic M, Denton CP, Furst DE, et al. Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 randomised, double-blind, placebo-controlled trial. Ann Rheum Dis 2011;70(1): 32-38.

27. Summary of Product Characteristics. Tracleer, 2010.

Labels
Dermatology & STDs Paediatric rheumatology Rheumatology
Login
Forgotten password

Don‘t have an account?  Create new account

Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account